Mirna Therapeutics and collaborators at the University of Zurich reported last week that the company's therapeutic microRNA-34a mimic, dubbed MRX34, could inhibit tumor growth in an animal model of lymphoma, expanding the potential use of the agent to new cancer types.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.